The diabetes tech firm boosts its full-year outlook after reporting 13% revenue growth in Q2 2026.
DexCom increased its 2026 revenue guidance to a range of $5.18 billion to $5.25 billion, up from prior expectations. The adjustment follows a 13% year-over-year revenue increase in Q2 2026, with organic growth at 12%.
The company cited strong performance in its U.S. market, targeting nearly 50% conversion of G7 15-day users by year-end. Comparable growth in Q2 2025 was not disclosed, but the current print exceeds recent trends.
Management attributed the outlook lift to operational execution and demand for its continuous glucose monitoring systems.